VibroSense Dynamics announces delayed deliveries to China

The first delivery of VibroSense Meter II instruments to China is delayed to the spring of 2026 due to organizational changes and uncertainties at VibroSense’s distributor UMCare in China. The binding distribution agreement with UMCare remains in force; however, it will not generate previously anticipated revenues during the autumn of 2025.

 “We continue to see significant opportunities in China, where both research and clinical activity within the field of diabetes are strong. The diabetes market in China is huge, and there is a substantial need for improved diagnostic tools for diabetic neuropathy,” says Toni Speidel, CEO of VibroSense Dynamics.

VibroSense Dynamics’ Key Account Manager in China continues to collaborate with UMCare to prepare for the market launch and to ensure a successful introduction once deliveries commence.

Contact

Toni Speidel, CEO of VibroSense Dynamics AB
Tel: +46 40 88 026
Email: [email protected]
www.vibrosense.se

About VibroSense Dynamics AB (publ)

VibroSense Dynamics AB (publ) develops and sells medical devices and services to facilitate diagnosis of nerve damage in the hands and feet. The method is based on measuring and quantifying the ability to perceive vibrations applied to the skin at multiple frequencies. The company's customers include diabetes clinics, occupational health providers, hospitals, primary care centers, and researchers.

Our vision that the company's products shall become a standard tool in all neurological examinations, to detect early signs of sensory changes so that patients and healthcare providers can take preventive action to avoid, reduce, or delay the onset of nerve damage in the hands and feet.